Sarepta Therapeutics Announces FDA Accelerated Approval of EXONDYS 51™ (eteplirsen) injection, an Exon Skipping Therapy to Treat Duchenne Muscular Dystrophy (DMD) Patients Amenable to Skipping Exon
Go back to Sarepta Therapeutics Announces FDA Accelerated Approval of EXONDYS 51™ (eteplirsen) injection, an Exon Skipping Therapy to Treat Duchenne Muscular Dystrophy (DMD) Patients Amenable to Skipping Exon| SAREPTA THERAP (NASDAQ: SRPT) | Delayed: 20.14 +0.03 (0.15%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $20.11 | 52 Week High | $63.73 | |||
| Open | $20.29 | 52 Week Low | $8.00 | |||
| Day High | $20.50 | P/E | N/A | |||
| Day Low | $19.97 | EPS | $-5.69 | |||
| Volume | 1,756,601 | |||||
